Sphingosylphosphorylcholine (SPC) is an important bioactive molecule, involved in many cellular processes. We have recently identified two specific, high-affinity receptors for SPC (OGRI and GPR4). In Swiss 3T3 cells. SPC induces growth inhibition through OGR1 and growth stimulation through GPR4. In HEY ovarian cancer cells, SPC induces inhibition of both growth and Akt kinase activity. Our overall objective is to investigate the signaling mechanisms controlling the different cellular effects induced by SPC through its receptors. We hypothesize that p38 MAP kinase plays a critical role in mediating the growth inhibitory effect of SPC. p38 is differentially regulated through different SPC receptors. Inhibition of Akt may be involved in growth inhibition and apoptosis. These hypotheses will be achieved through two Specific Aims:
Specific Aim 1. To determine the role and regulatory mechanisms of p38 MAP kinase and Akt in the growth inhibitory/stimulatory effects of SPC through OGR1 and GPR4 in Swiss 3T3 cells. We will 1.1) identify the respective G protein(s) coupled to OGR1 and GPR4, those that mediate the growth inhibitory and stimulatory effects of SPC; 1.2) investigate whether p38 MAP kinase is necessary and/or sufficient for SPC-induced growth inhibition; 1.3) determine the role of ERK in SPC-induced growth regulation and p38 activation; 1.4) examine the role of PLC-PKC in SPC-induced growth regulation; and 1.5) determine whether Akt is differentially regulated by GPR4 and OGR1 and its role in SPC-induced growth regulation.
Specific Aim 2. To determine the role and signaling mechanisms of p38 MAP kinase and Akt in growth and cell survival regulated by SPC in HEY ovarian cancer cells. We postulate that SPC inhibits Akt activation by inhibiting phosphorylation at T308, leading to either inhibition of growth, prevention of cell survival, and/or induction of apoptosis. We will test this hypothesis by 2.1) determining whether ERK, p38, PLC, and PKC are required for the growth inhibitory effect of SPC; 2.2) investigating the signaling mechanisms of SPC-induced inhibition of the Akt kinase activity and determining whether Akt kinase inhibition is involved in SPC-induced growth inhibition; and 2.3) determining whether SPC-induced Akt activation induces chemo-sensitization. The focus of this study is to determine how p38 MAP kinase and Akt are differentially regulated in Swiss 3T3 and HEY cells by SPC through its two receptors and how these differential activations of p38 and Akt lead to distinct cellular effects. Our long-term goals are to understand the physiological and pathological roles of SPC and its receptors and to discover new target(s) or signaling pathways affecting tumor cell growth and/or metastasis. These studies may lead to novel therapies to treat highly malignant ovarian cancer, as well as other tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA089228-04
Application #
6882645
Study Section
Physiological Chemistry Study Section (PC)
Program Officer
Yassin, Rihab R,
Project Start
2002-04-01
Project End
2006-01-31
Budget Start
2005-04-01
Budget End
2006-01-31
Support Year
4
Fiscal Year
2005
Total Cost
$92,183
Indirect Cost
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Xu, Yan; Wang, Dongmei; Wang, Zeneng (2009) Lipid generation and signaling in ovarian cancer. Cancer Treat Res 149:241-67
Li, Hui; Wang, Dongmei; Singh, Lisam Shanjukumar et al. (2009) Abnormalities in osteoclastogenesis and decreased tumorigenesis in mice deficient for ovarian cancer G protein-coupled receptor 1. PLoS One 4:e5705
Li, Hui; Wang, Dongmei; Zhang, Hong et al. (2009) Lysophosphatidic acid stimulates cell migration, invasion, and colony formation as well as tumorigenesis/metastasis of mouse ovarian cancer in immunocompetent mice. Mol Cancer Ther 8:1692-701
Wang, Dongmei; Zhao, Zhenwen; Caperell-Grant, Andrea et al. (2008) S1P differentially regulates migration of human ovarian cancer and human ovarian surface epithelial cells. Mol Cancer Ther 7:1993-2002
Tager, Andrew M; LaCamera, Peter; Shea, Barry S et al. (2008) The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 14:45-54
Singh, Lisam Shanjukumar; Berk, Michael; Oates, Rhonda et al. (2007) Ovarian cancer G protein-coupled receptor 1, a new metastasis suppressor gene in prostate cancer. J Natl Cancer Inst 99:1313-27
Zhang, Zhongjian; Lee, Yi-Ching; Kim, Sung-Jo et al. (2007) Production of lysophosphatidylcholine by cPLA2 in the brain of mice lacking PPT1 is a signal for phagocyte infiltration. Hum Mol Genet 16:837-47
Zaslavsky, Alexander; Singh, Lisam Shanjukumar; Tan, Haiyan et al. (2006) Homo- and hetero-dimerization of LPA/S1P receptors, OGR1 and GPR4. Biochim Biophys Acta 1761:1200-12
Zhao, Xiaoxian; Wang, Dongmei; Zhao, Zhenwen et al. (2006) Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells. J Biol Chem 281:29357-68
Kim, Kwan-Sik; Sengupta, Saubhik; Berk, Michael et al. (2006) Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 66:7983-90

Showing the most recent 10 out of 14 publications